(Sharecast News) - N4 Pharma announced the appointment of Dr David H Solomon as its chief executive on Tuesday, and unveiled plans to rebrand as Thalia Therapeutics as it pivoted towards becoming an RNA therapeutics-focused biotechnology company.
The AIM-traded group said it was expanding its pipeline beyond its proprietary Nuvec gene...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE